Allianz’s Alnylam Pharmaceuticals ALNY Stock Holding History

Allianz’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-760	Closed	-$209K	–	434
2024 Q3	$209K	Buy	+760	New	+$198K	0.01%	296

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Allianz's ALNY Position: Q4 2024 in Review

Allianz sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2024, closing a stake of 760 shares — an estimated $209K sold.

Allianz first reported a position in ALNY in Q3 2024 and held it in 1 quarter. The position peaked at $209K in Q3 2024. 595 funds tracked by Wall St. Rank hold ALNY as of Q4 2024.

Allianz reported no remaining Alnylam Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Allianz sold 760 Alnylam Pharmaceuticals shares in Q4 2024, an estimated $209K.
Allianz first reported a position in Alnylam Pharmaceuticals in Q3 2024 and held it in 1 quarter.
Allianz's Alnylam Pharmaceuticals position peaked at $209K in Q3 2024.
595 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2024.

Based on Allianz's 13F filing for Q4 2024, filed 12 Feb 2025.